CAS
ACAD icon

CTC Alternative Strategies’s Acadia Pharmaceuticals ACAD Stock Holding History

CTC Alternative Strategies’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-55,133
Closed -$1.01M – 93
2024
Q4 		$1.01M Buy
+55,133
New +$890K 1.22% 14

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

CTC Alternative Strategies's ACAD Position: Q1 2025 in Review

CTC Alternative Strategies sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 55,133 shares — an estimated $1.01M sold.

CTC Alternative Strategies first reported a position in ACAD in Q4 2024 and held it in 1 quarter. The position peaked at $1.01M in Q4 2024. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

  • CTC Alternative Strategies reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • CTC Alternative Strategies sold 55,133 Acadia Pharmaceuticals shares in Q1 2025, an estimated $1.01M.
  • CTC Alternative Strategies first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • CTC Alternative Strategies's Acadia Pharmaceuticals position peaked at $1.01M in Q4 2024.
  • 320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on CTC Alternative Strategies's 13F filing for Q1 2025, filed 16 May 2025.